Johnson & Johnson Reports Five-Year SPARTAN Data for Erleada in Non-Metastatic CRPC

Johnson & Johnson today presented five-year overall survival data from the Phase 3 SPARTAN trial evaluating Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer. The data showed a significant improvement in overall survival with Erleada, with a median overall survival of 73.9 months compared to 59.9 months in the placebo arm.